Products

Keshif

Lowering the barriers to data insights

keshif.me Data & Analytics / BI & Dashboards

AI Benchmark
Desktop
Mobile
Monthly visits
<5K
Oct 2026
Public revenue
Undisclosed
No public revenue evidence yet
Entry price
Unknown
No monthly subscription pricing
Creators
Adil Yalcin
@keshifme· 321 followers
Launched
9y ago
2017-06-25 · Est.

Traffic

Monthly visitsData through Oct 2026

Marketing moves

Launches, search & content, referrals, promotions
X accounts@keshifme

  • Launched on Product HuntLaunch

    Turns data into a beautiful live dashboard in seconds.

    May 23, 2018 · 8y agoLaunch page

  • Launched on Product HuntLaunch

    Data visualization tools

    Jun 25, 2017 · 9y agoLaunch page

Traffic sources

Oct 2026

Traffic breakdown

Channels

  • Direct39%
  • Organic Search33%
  • Referrals10%
  • Social6%
  • Other12%

Countries

  • India71%
  • United States17%
  • Poland11%

Search

Domain authority —Domain registered 2014-10-10

KeywordMonthly volume
data viz tree roots370
qlik sense scatter logarithm scale370
how do i shrink the axes of a scatter plot excel330
price percentile preseantion chart60
how to change the color of scatter plot in excel40

Traffic data: Vaneform

Pricing

Pricing page not identified yet, or no public pricing listed.

Pages & changes

Tracked since 2018-05-23

Key pages

Weekly snapshots
keshif.me/ Snapshot 2026-11-04

Changes

No pricing, plan, or positioning changes detected since tracking started.

Questions & evidence

How much website traffic does Keshif get?
Vaneform estimates <5K website visits in 2026-10. Visits can include repeat visits; this estimate measures web traffic separately from paying customers or revenue.Source
What is Keshif and what platforms does it support?
Keshif is catalogued under BI & Dashboards: Lowering the barriers to data insights. Supported platforms: Web.

Related products in this category

Data & Analytics / BI & Dashboards

These products share a catalog category. Compare customer tasks, features and deployment requirements before treating them as alternatives.